I believe NICE should also be aware that in due course (in it's forthcoming combination forms) DCVax will ultimately actually save the NHS money. Naysayers only look at the probable cover price of DCVax and compare it directly to existing drugs instead of whole treatment regimes thereby failing to take into account the vast additional costs associated with adjunctive/ supportive care from chemotherapy & radiation toxicity as well as immune-related adverse events (irAEs) from immunotherapies. Over 2,100 doses of DCVax-L were administered during the Phase III trial and only 5 serious adverse events were possibly related to the treatment (none were classed as life threatening (Grade-4) or lead to Death (Grade-5). This is unprecedented and strongly suggests that supportive care costs will be substantially lower. Not to mention palliative care costs will be reduced as more patients are cured! Yes, cured!
DCVax has known safety advantages over CAR-T therapies and bare in mind that amongst other CAR-T lymphoma treatments that have also received approval, NICE approved (under a managed access agreement) brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia, which is estimated to cost ~$530,000 for one single infusion!
So, FUDsters can whine all they want, but I dont see the NICE appraisal for NHS coverage of DCVax-L being a problem! Possibly a managed access agreement to begin with, but ultimately it will get full coverage in due course once automated (EDEN) pricing is involved and the benefits have been understood in practice.
AI
Market Data 
Markets 
